AI Analysis | Feedback

Here are 1-3 brief analogies for Biogen (BIIB):

• Like Amgen, but with a primary focus on developing therapies for neurological and neurodegenerative diseases.
• Think of it as Eli Lilly, but largely dedicated to finding treatments for disorders of the brain and nervous system, such as MS and Alzheimer's.

AI Analysis | Feedback

• TECFIDERA: A therapy used for treating multiple sclerosis (MS).
• VUMERITY: A therapy used for treating multiple sclerosis (MS).
• AVONEX: A therapy used for treating multiple sclerosis (MS).
• PLEGRIDY: A therapy used for treating multiple sclerosis (MS).
• TYSABRI: A therapy used for treating multiple sclerosis (MS).
• FAMPYRA: A therapy used for treating multiple sclerosis (MS).
• SPINRAZA: A therapy specifically for spinal muscular atrophy (SMA).
• FUMADERM: A treatment for plaque psoriasis.
• BENEPALI: An etanercept biosimilar referencing ENBREL.
• ADUHELM: A therapy approved for the treatment of Alzheimer's disease.
• IMRALDI: An adalimumab biosimilar referencing HUMIRA.
• FLIXABI: An infliximab biosimilar referencing REMICADE.
• RITUXAN: A therapy for various conditions including non-Hodgkin's lymphoma, CLL, rheumatoid arthritis, vasculitis, and pemphigus vulgaris.
• RITUXAN HYCELA: A therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL).
• GAZYVA: A therapy used for chronic lymphocytic leukemia (CLL) and follicular lymphoma.
• OCREVUS: A therapy for relapsing and primary progressive multiple sclerosis (MS).
• Lecanemab: A therapy for Alzheimer's disease, developed in collaboration with Eisai Co., Ltd.
• BYOOVIZ: A biosimilar referencing Lucentis, used in ophthalmology.

AI Analysis | Feedback

AI Analysis | Feedback

• Genentech, Inc. (RHHBY)
• Ionis Pharmaceuticals, Inc. (IONS)
• Samsung Bioepis Co., Ltd.

AI Analysis | Feedback

Christopher A. Viehbacher

President and Chief Executive Officer

Christopher A. Viehbacher joined Biogen as President and Chief Executive Officer in November 2022. He has extensive international experience in both large pharmaceutical companies and entrepreneurial biotech companies. Viehbacher spent 20 years with GlaxoSmithKline and then served as the global CEO of Sanofi for six years (2008-2014), where he oversaw strategic acquisitions including the $20 billion purchase of Genzyme, and strengthened and diversified its R&D pipeline. In 2015, he co-founded Gurnet Point Capital, a Cambridge-based healthcare investment fund, which has led to the creation and development of many innovative companies. He has also chaired or been a member of the board of several entrepreneurial biotechnology companies.

Robin Kramer

Chief Financial Officer

Robin Kramer is the Chief Financial Officer at Biogen.

Priya Singhal, M.D., M.P.H.

Executive Vice President, Head of Development

Priya Singhal was named Executive Vice President and Head of Development at Biogen in January 2023, after serving as interim Head of Research and Development. She first joined Biogen in 2012 as Vice President Clinical Trials and Benefit-Risk Management, and rejoined in 2020 as Senior Vice President of Global Safety & Regulatory Sciences, with oversight for Japan and China R&D. Prior to her return to Biogen, Dr. Singhal served as Head of R&D and Manufacturing at Zafgen Inc., a clinical-stage biopharmaceutical company. She also held various roles at Vertex Pharmaceuticals and began her drug-development career at Millennium Pharmaceuticals.

Adam Keeney, Ph.D.

Executive Vice President, Head of Corporate Development

Adam Keeney joined Biogen as Executive Vice President and Head of Corporate Development in April 2023. He brings over 20 years of experience in R&D, business development, and strategy within biotech and large pharma. Most recently, he served as the Chief Executive Officer of NodThera, a clinical-stage biotech company. Before NodThera, Dr. Keeney was at Sanofi, where he was responsible for all of Sanofi Genzyme's business development activities, successfully completing several significant transactions. He also held business development roles at Johnson & Johnson and started his career as a discovery scientist at Lundbeck.

AI Analysis | Feedback

Here are the key risks to Biogen's business:

1. Loss of market share and revenue in the Multiple Sclerosis (MS) franchise due to generic and biosimilar competition and patent expirations: Biogen's long-standing and significant revenue stream from its MS drugs, such as Tecfidera and Tysabri, faces substantial erosion from generic and biosimilar competition. The invalidation of key patents for Tecfidera in the U.S. has already led to a significant reduction in revenue from this drug. While Biogen has secured some patent protection in Europe until 2028, it faces ongoing legal challenges and competitive pressures from biosimilars like Sandoz's Tyruko, leading to a projected mid-teens erosion in legacy MS product sales.
2. Challenges with Alzheimer's disease treatments, including safety concerns, slow commercial adoption, and competition: Biogen has faced significant hurdles in its Alzheimer's pipeline. Its previous drug, Aduhelm, had a controversial launch due to questions about its clinical benefit and safety concerns like brain swelling and bleeding, ultimately leading Biogen to halt its sales and development. While its newer Alzheimer's drug, Leqembi (co-developed with Eisai), shows promise, its sales growth has been slower than anticipated due to issues such as PET scan reimbursement problems and slow updates to hospital protocols. Leqembi also carries warnings about serious side effects, including amyloid-related imaging abnormalities (ARIA), characterized by brain swelling and bleeding. Furthermore, the entry of competitors like Eli Lilly's Kisunla is creating a more crowded market, potentially limiting Leqembi's growth.
3. Overall declining revenue and earnings per share (EPS): Biogen has experienced a downward trend in its revenue and EPS in recent years. Its revenue has been falling since 2020, with analysts projecting continued declines. This indicates broader challenges in the company's ability to generate consistent growth and profitability, stemming from the pressures on its core MS business and the difficulties in effectively commercializing new products, particularly in the Alzheimer's space.

AI Analysis | Feedback

AI Analysis | Feedback

Biogen Inc. operates in several key therapeutic areas with significant addressable markets globally and in specific regions.

Multiple Sclerosis (MS)

The global multiple sclerosis therapeutic market was estimated at USD 27.39 billion in 2024 and is projected to reach USD 38.62 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.93% from 2025 to 2030. Another estimate places the global market at USD 27.6 billion in 2024, growing to USD 38 billion by 2030. North America holds the largest share of this market, accounting for 38.28% in 2024. The U.S. multiple sclerosis market size alone was approximately USD 16 billion in 2024.

Key Biogen products for MS include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and OCREVUS. While Tecfidera's sales have significantly declined due to generic competition, dropping from a peak of $4.4 billion in 2019 to $1.4 billion in 2022, Ocrevus (developed with Roche) is a significant player with global sales projected to reach $7.6 billion by 2028.

Spinal Muscular Atrophy (SMA)

The global spinal muscular atrophy treatment market was valued at USD 4.40 billion in 2024 and is projected to reach USD 13.09 billion by 2030, exhibiting a CAGR of 18.0% from 2025 to 2030. Other forecasts indicate the market could reach nearly USD 20.06 billion by 2033, growing at a CAGR of 16.5%. North America dominates this market, holding a 68.4% revenue share in 2024. The U.S. market for SMA treatment is expected to generate US$2.07 billion in sales in 2025. The spinal muscular atrophy market across the seven major markets (7MM: US, France, Germany, Italy, Japan, Spain, and the UK) is projected to grow from $2.7 billion in 2023 to $3 billion in 2033. The U.S. alone accounts for 56.5% of the 7MM sales in 2023.

Biogen's main product in this area is SPINRAZA.

Alzheimer's Disease

The Alzheimer's disease therapeutics market across the 7MM (United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan) was approximately USD 3,610 million in 2023. This market is anticipated to increase to approximately USD 5,048 million in 2025 and is projected to reach USD 34,335 million by 2034, with a CAGR of 23.7%. The global Alzheimer's therapeutics market size was estimated at USD 4.05 billion in 2022 and is anticipated to reach USD 15.19 billion by 2030. Similarly, the global Alzheimer's drug market size was estimated at USD 4.08 billion in 2025 and is projected to reach USD 6.38 billion by 2034. North America held the largest share of the Alzheimer's therapeutics market, exceeding 40.79% in 2022, and 51.55% of the Alzheimer's drugs market in 2025. The U.S. Alzheimer's drug market size was USD 1.48 billion in 2024 and is projected to be around USD 2.73 billion by 2034.

Biogen's product ADUHELM for Alzheimer's disease was discontinued from development and commercialization by November 2024 due to minimal market uptake. Biogen also partners with Eisai Co., Ltd. on Lecanemab (Leqembi) for Alzheimer's disease.

AI Analysis | Feedback

Biogen (BIIB) is expected to drive future revenue growth over the next 2-3 years through several key strategies, primarily focusing on the expansion and commercialization of recently launched products and advancements in its pipeline. While the company anticipates continued declines in its legacy multiple sclerosis (MS) franchise due to competitive pressures, a "new Biogen" is emerging, propelled by its newer therapies.

Expected Drivers of Future Revenue Growth:

1. Growing Sales of Leqembi (Lecanemab) for Early Alzheimer's Disease: Leqembi is a significant growth driver for Biogen. After a slow start, sales are gaining momentum, with strong growth reported in recent quarters. The anticipated approval and broader reimbursement of a subcutaneous injection formulation in the U.S., along with marketing authorizations in the European Union, Japan, and China, are expected to further accelerate its uptake and global reach.
2. Continued Expansion of Skyclarys (Omaveloxolone) for Friedreich's Ataxia: Skyclarys, a treatment for the rare neurodegenerative disorder Friedreich's ataxia, is consistently highlighted as a strong performer and a key contributor to Biogen's revenue growth. The drug has received approvals in the U.S., Europe, the U.K., and Brazil, and its geographic expansion is ongoing.
3. Increasing Demand for Zurzuvae for Postpartum Depression (PPD): Zurzuvae, a recently launched treatment for postpartum depression, has demonstrated strong demand growth and is exceeding initial sales expectations. Its approval in the European Union is expected to further contribute to its revenue potential.
4. Uptake of High-Dose SPINRAZA (nusinersen) for Spinal Muscular Atrophy (SMA): The European Commission has approved a higher-dose regimen of Spinraza, which is considered more effective. An anticipated FDA decision on this high-dose regimen by April 2026 is expected to bolster revenue from this established product.
5. Pipeline Advancements and Strategic Business Development: Biogen is strategically expanding its late-stage pipeline, with programs such as litifilimab for systemic lupus erythematosus (with Phase 3 data readouts expected in the second half of 2026) and other early-stage assets. The company's strategic acquisitions, such as Reata Pharmaceuticals (which brought in Skyclarys) and Alcyone Therapeutics, along with collaborations, are crucial for diversifying its portfolio and fueling future growth.

AI Analysis | Feedback

Share Repurchases

• Biogen's 2020 Share Repurchase Program authorized up to $5.0 billion of common stock, with approximately $2.1 billion remaining available as of March 31, 2024.
• The company repurchased $750 million worth of common stock in 2022.
• In 2021, Biogen repurchased a total of $1.8 billion in common stock.

Share Issuance

• Biogen issued 169.5 million shares of common stock in 2024.
• In 2023, 168.7 million shares of common stock were issued.
• In 2022, 167.9 million shares of common stock were issued.

Outbound Investments

• Biogen acquired Human Immunology Biosciences (HI-Bio) in July 2024 for an upfront payment of $1.15 billion, with up to an additional $650 million tied to potential development milestones.
• The company acquired Reata Pharmaceuticals, Inc. in July 2023 for approximately $7.3 billion.
• Biogen acquired Alcyone in September 2025 for $85 million.

Capital Expenditures

• Capital expenditures were approximately $154 million in 2024, $246.3 million in 2023, and $240 million in 2022.
• Capital expenditures for the third quarter of 2025 were approximately $46 million.
• The primary focus of capital expenditures includes advancing new medicines, particularly in the Alzheimer's disease pipeline, and investing in a smaller set of high-conviction clinical-stage programs to diversify the portfolio.